We report on systemic delivery and long-term biological effects of apolipoprotein E (apoE) obtained by intramuscular (i.m.) plasmid DNA injection. ApoE plays an important role in lipoprotein catabolism and apoE knock-out mice develop severe hypercholesterolemia and diffuse atherosclerosis. We have injected apoE-deficient mice with 80 g of a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA under the control of the CMV promoter-enhancer in both posterior legs. Local expression of the transgene was demonstrated throughout 16 weeks. Human apoE3 recombinant protein reached 0.6 ng/ml serum level. After i.m. injection of pCMV-E3 expression vector the mean serum cholesterol concentrations decreased from 439 ± 57 mg/dl to 253 ± 99 mg/dl (P Ͻ 0.05) 2 weeks after injection and persisted at a
Introduction
Apolipoprotein E (apoE) is a component of all plasma lipoproteins other than LDL. 1 ApoE plays a major role in lipoprotein catabolism through its interaction with the LDL-receptor (LDL-R) and a putative remnant receptor, LDLR-related protein (LRP), and possibly via other receptors. 1, 2 In addition to lipoprotein transport, apoE is a component of the reverse cholesterol transport system, which delivers excess cholesterol from peripheral tissues to the liver for metabolism and elimination. 1, 2 A reduction in plasma cholesterol levels and an accelerated clearance of plasma lipoproteins after apoE intravenous infusion occurs in cholesterol-fed normal rabbits and Watanabe heritable hyperlipidemic rabbits (WHHR). 3, 4 Transgenic mice overexpressing apoE showed a sustained reduction of plasma cholesterol concentration, resistance to cholesterol-rich diet and enhanced clearance of VLDL, LDL and chylomicron rem- significantly reduced level throughout the 16 weeks observation period (P Ͻ 0.005). Serum cholesterol was unaffected and reached an absolute level of 636 ± 67 mg/dl in control groups. Finally, injection of pCMV-E3 into apoE-deficient mice resulted in a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol. These results demonstrate that severe hypercholesterolemia in apoE-deficient mice can be effectively reversed by i.m. DNA injection, and indicate that this approach could represent a useful tool to correct several hyperlipidemic conditions resulting in atherosclerosis. Gene Therapy (2000) 7, 1795-1801.
nants from blood. 5, 6 These observations support the hypothesis that apoE supplementation may result in the correction of dyslipidemia. Decreased serum cholesterol levels and increased lipoprotein clearance have been detected in apoE-deficient mice after bone marrow transplantation from syngenic healthy donors. 7 Phenotypic reversion of the hypercholesterolemic state in apoEdeficient mice has been reported after in vivo gene transfer with an adenoviral vector containing human apoE cDNA. 8, 9 Furthermore, cholesterol reduction has recently been demonstrated after transplantation of apoE secreting endothelial cells into apoE-deficient mice. 10 These findings highlight the great opportunity offered by apoE gene replacement.
In a previous study we demonstrated for the first time accumulation of defective apoE in Yoshida dislipidemic rat plasma after direct intramuscular (i.m.) injection of a plasmid vector encoding apoE2 cDNA. 11 I.m. injection of naked plasmid DNA to produce a secreted protein has distinct advantages compared with other gene transfer strategies: (1) plasmid vectors are relatively simple to construct, can accept large cDNA inserts, and homogeneous preparations can be produced easily and economically without the risk of contamination with wild-type infectious particles; (2) the injected DNA is maintained in an episomal, circular form, thus making the possibility of an undesired insertional mutagenesis very unlikely; 12 (3) plasmid naked DNA strategy is not complicated by immune responses against vector per se that have been associated with adenovirus-mediated gene transfer. 13, 14 Disadvantages in i.m. injection of naked DNA are represented by the inefficient uptake by muscle cells and the consequent low level expression compared with viral vectors. 15 Nevertheless, secretion in blood plasma and/or systemic biological activity of the transgene have been confirmed after i.m. delivery of plasmid vectors encoding for erythropoietin, 16 factor VII, 17 rat kallikrein-binding protein (RKBP), 18 vascular endothelial growth factor (VEGF), 19 interleukin 10, 20 and interferon-␥ receptor/IgG1 fusion protein. 21 These studies suggest that i.m. injection of expression plasmid DNA provides a new approach to in vivo delivery of proteins for therapeutic purposes.
To investigate the potential use of i.m. injection of naked DNA in gene therapy of hyperlipidemias, we injected apoE-deficient mice with a plasmid vector (pCMV-E3) encoding the human apoE3 cDNA driven by the CMV promoter-enhancer. We found that i.m. injection of pCMV-E3 determines local expression of the encoded protein and detectable levels of human apoE in the systemic circulation for several weeks after the injection. ApoE-deficient mice injected with pCMV-E3 showed significantly lower cholesterol levels than control animals (P Ͻ 0.005). In addition, a redistribution of cholesterol content between lipoprotein fractions, with a marked decrease in VLDL, IDL and LDL cholesterol content and an increase in HDL cholesterol content, was demonstrated in pCMV-E3 injected mice compared with lipoprotein distribution of control groups. These results indicate that reduced cholesterol values and the changes in lipoprotein profile observed in pCMV-E3 injected animals reflect production, secretion and biological activity of recombinant human apoE by the injected muscle.
Results
PCR detection of human apoE mRNA in mouse skeletal muscle Human apoE3 cDNA was inserted into pCMV5 expression vector containing the strong CMV immediateearly (CMV-IE) promoter-enhancer. 11 The expression capacity of the resulting pCMV-E3 plasmid was determined by a specific enzyme linked immunoabsorbent assay (ELISA) following transient transfection. Secreted human apoE was measured in the culture supernatant (data not shown).
We next analyzed by RT-PCR the presence of human apoE mRNA in mouse muscle injected with pCMV-E3 vector to qualitatively monitor the expression of apoE in the muscle of injected mice. Six-to 7-week-old apoEdeficient mice were injected with 80 g of naked pCMV-E3 plasmid vector or pCMV5 control vector in both rectus femoris muscles (160 g of DNA per treatment). As shown in Figure 1 , human apoE3 is transcribed in the mouse muscle injected with pCMV-E3 vector (n = 6), and not in control mice injected with pCMV5 (n = 3) or C57 untreated normal mice (n = 3). Human apoE mRNA levels were detectable at 1, 4 and 16 weeks after the injection. Secretion of human apoE in mouse serum Sera were obtained from nine apoE-deficient mice injected with pCMV-E3, 10 apoE-deficient mice injected with pCMV5, and eight untreated apoE-deficient mice. Human apoE levels were measured by a specific ELISA assay in pooled sera from each group. As shown in Figure 2, human apoE levels in pCMV-E3 injected mice were 0.6 ng/ml 1week after injection, and human apoE was still detectable 4 weeks after the injection. ApoE-deficient mice untreated or injected with pCMV5 control vector had no detectable human apoE in the circulation.
Effect of i.m. injection of pCMV-E3 on serum cholesterol levels
The evidence that human apoE is locally expressed and systemically secreted into mouse serum after i.m. injection of pCMV-E3 led us to study the biological activity of the recombinant protein. Total cholesterol levels from apoE-deficient mice injected with pCMV-E3 vector (n = 9)
Figure 2 Serum apoE levels after i.m. injection of pCMV-E3. Human apoE levels were measured on pooled sera from apoE-deficient mice not injected (apoE-KO), from apoE-deficient mice injected with pCMV5 control vector and from apoE-deficient mice injected with pCMV-E3, 1 and 4 weeks after DNA injection. Recombinant protein was demonstrated in sera from pCMV-E3 injected mice, but not in sera from control groups at each time-point.
Long-term systemic biological effects of apolipoprotein-E M Rinaldi et al 1797 or pCMV5 control vector (n = 10) were monitored before and after the injection, from week 0 until week 16. The results obtained are illustrated in Figure 3 . A clear decrease in serum cholesterol levels was found after injection with pCMV-E3 vector, in contrast with mice injected with control vector. Mean serum cholesterol levels decreased from a pre-injection value of 439 ± 57 mg/dl to 253 ± 99 mg/dl 2 weeks after injection, and remained significantly lower up to 16 weeks (P Ͻ 0.005, ANOVA two tails). In apoE-deficient mice injected with pCMV5 control vector mean serum cholesterol levels increased from a pre-injection value of 484 ± 12 mg/dl to an absolute level of 636 ± 67 mg/dl 16 weeks after the injection, as typical in this animal model. In addition, a statistically significant difference from week 2 onwards was also found when serum cholesterol levels from pCMV-E3 injected mice and pCMV5 control group were compared at each time-point (P Ͻ 0.05, t-test). At 16 weeks after injection, serum cholesterol in pCMV5-injected control mice was 636 ± 67 mg/dl, whereas the mean serum cholesterol in the pCMVE3-injected mice was down to 279 ± 71 mg/dl (P Ͻ 0.0005). In order to include additional negative controls, apoE-deficient mice (n = 8) were injected using a different plasmid vector called pRC112-HCV that expresses the antigenic domain of the HCV NS3 C terminus. 22 The sera cholesterol levels in each mouse were examined from week 0 until week 16. As expected for untreated apoE-deficient mice, we did not observed a significant reduction in serum cholesterol after treating these animals with pRC112-HCV control vector. Their cholesterol levels were similar to those found in pCMV5-injected mice (Figure 3) . Figure 4 shows the lipoprotein distribution of apoEdeficient mice injected with pCMV-E3 or pCMV5 control vector and the lipoprotein distribution of C57BL untreated normal mice (n = 8). Pooled sera from each group were FPLC fractionated and the cholesterol content was measured in each fraction across the elution profile. In pCMV-E3 injected mice, determination was done 6 and 8 weeks after injection, whereas pCMV5 injected mice were tested at 6 weeks after injection. In C57BL untreated normal mice the lipoprotein elution profile showed that cholesterol eluted mostly in the HDL fraction, whereas in pCMV5 injected mice, as expected for apoE-deficient mice, cholesterol eluted mostly in the VLDL-LDL fraction. 23, 24 ApoE-deficient mice injected with pCMV-E3 showed a marked decrease of both VLDL and IDL-LDL cholesterol content with a mild increase of the HDL fractions (Figure 4 ).
Effect of i.m. injection of pCMV-E3 on serum lipoproteins distribution

Discussion
In this study we demonstrate that i.m. injection of expression plasmid DNA encoding human apoE3 produces sufficient amounts of apoE to obtain a significant decrease of serum cholesterol concentration, as well as a consistent modification of lipoprotein profile in hypercholesterolemic apoE-deficient mice.
The human apoE in these mice was identified at both mRNA and protein levels. Expression of the human apoE in injected muscle was detected by qualitative RT-PCR analysis for as long as 16 weeks after gene transfer. This result is in agreement with previous studies from Jiao et al. 25 These authors demonstrated that the expression of naked plasmid DNA in the myofibers of nonhuman primate muscle persisted for at least 4 months.
We also demonstrated that apoE was being secreted by the muscle, as indicated by the ELISA assay performed on sera from injected animals. However, apoE secretion did not reach very high levels in the sera of the experimental animals (less than 1% of the endogenous apoE level found in normal mice). 26 One possible explanation is the rapid cycling due to the high levels of cholesterol. 10 In fact, apoE protein could be quickly associated with lipids, taken up by the cells and transported to the tissues, thus resulting in a low serum concentration in these animals. In mice a large portion of the hepatic apoB (a ligand for the LDL-R along with apoE) is truncated (apo B48) and does not contain the LDL-R binding domain. Whereas wild-type mouse VLDL and IDL contain equal portions of apo B100 (the full length protein) and apo B48, VLDL and IDL from apoE-deficient mice contain approximately 20-fold higher apo B48 than apo B100. 23 This increment reflects the impaired apoE-dependent clearance of these VLDL remnants. Due to the low levels of apo B100 which generate this altered compensatory mechanism for hepatic clearance of VLDL and IDL, apoE is essential in mice for catabolizing these lipoproteins. 27 Thus, it is feasible that circulating lipoproteins containing apoE in pCMVE3-treated mice are cleared very quickly by the liver, which could render the serum apoE quite undetectable.
Altogether, our results on mRNA expression and protein secretion demonstrate that i.m. injection of pCMV-E3 yields detectable levels of apoE in the systemic circulation and that apoE production persists for several weeks after DNA injection.
We next examined the biological activity of the recombinant protein in terms of effects of apoE secretion on lipoprotein metabolism. As control groups, apoEdeficient mice were injected with pCMV5 empty plasmid or pRC112-HCV plasmid, coding for an unrelated foreign protein. 22, 28 These control groups were used in order to exclude the possibility of a non-specific mechanism by which an immune response to the vector components or the foreign transgene results in a non-specific reduction in serum cholesterol. We showed that the appearance of apoE in the blood of apoE-deficient mice injected with pCMV-E3 was associated with a dramatic reduction of serum cholesterol levels, as compared with control mice. Serum cholesterol dropped in pCMVE3-treated mice 2 weeks after injection and remained significantly low up to 16 weeks (P Ͻ 0.005), ranging from 253 ± 99 to 329 ± 59 mg/dl. As is typical in this animal model, 10,27 the cholesterol levels increased in control groups reaching 636 ± 67 mg/dl in pCMV5-injected mice 4 months after injection. At this time-point serum cholesterol concentration was down to 279 ± 71 mg/dl in pCMVE3-injected mice (P Ͻ 0.0005).
Human apoE3 concentration was detectable at the first week after pCMV-E3 injection (0.6 ng/ml). The apparent delay in serum cholesterol reduction at the second week following pCMV-E3 injection was possibly due to the accumulation of apoE3 during the first week. The availability of apoE3 in the serum may be rate limiting in the clearance of lipoproteins since apoE-containing lipoproteins bind to LDL receptors with a 20-25-fold greater affinity than do LDL. 29, 30 This enhanced binding is mediated by the interaction between multiple apoE molecules on the surface of the lipoproteins with LDL receptors. 29, 30 This could explain the accumulation of the secreted protein observed during the first week and the subsequent reduced circulating level due to the reduction of apoE-containing lipoproteins.
Moreover, results from several authors indicate a nondirect correlation between apoE concentration and total serum cholesterol reduction. After intravenous adenovirus-mediated gene transfer significant reduction of total serum cholesterol was achieved in apoE knock-out mice without straight correlation with human apoE concentrations at different time-points. 8 Following bone marrow transplantation in apoE knock-out mice, apoE levels as low as 1.89-3% of the concentration found in normal mice reduced serum cholesterol levels owing to a reduction of VLDL and LDL. 31 Bellosta et al, 32 by macrofage-specific expression of human apoE in apoE knockout mice, found that human apoE reached 3-8% of the level of mouse apoE. Nevertheless, they demonstrated significantly reduced plasma cholesterol levels and decreased atherosclerotic lesions. The normalization or reduction of the cholesterolemia after apoE3 gene transfer or normal bone marrow transplantation in apoE knockout mice has been demonstrated even in the absence of detectable levels of serum apoE. 10, 27 The complex of these results definitely prove the hypothesis that very small amount of apoE are sufficient to enhance hepatic clearance of VLDL and IDL cholesterol in apoE knock-out mice. 27, 32 Using fast protein liquid chromatography (FPLC) analysis we showed that the decrease in total serum cholesterol was accompanied by changes in the serum lipoproteins distribution. A marked decrease in VLDL, IDL and LDL cholesterol, and a mild increase in HDL cholesterol, was evident in apoE-deficient mice injected with pCMV-E3 but not in control mice.
The complex of our data demonstrates that i.m. injection of apoE-expressing plasmid DNA results in a partial reversion of apoE-deficient mice phenotype.
ApoE delivery has been reported by several different methods. Bone marrow transplantation strategies have been powerfully used for gene delivery of apoE after irradiation. 7, 27, 31 Alternatively, adenovirus-based gene transfer techniques have also been described. 8, 9 Lastly, endothelial cells and epidermal keratinocytes expressing the apoE have also been used. 10, 33 Because of its unique properties, skeletal muscle was chosen in our study as the target tissue for gene transfer. 12, 34 Currently available vectors for gene delivery to muscle include several viral vectors. Adenoviral vectors are very efficient at delivering genes to many different tissues; however, at this moment the induction of a strong immunological response against viral vector proteins significantly limits their extensive application. 35 Retroviral vectors require dividing cells for nuclear entry, 36 thus cannot be used for efficient gene delivery to uninjured muscle. 37, 38 Retroviral vectors have been used ex vivo to genetically modify dividing myoblasts, 39 followed by surgical implantation; however, the requirement for substantial tissue-culture manipulation and surgical expertise limit their ordinary use in man. Therefore, the development of a simple, safe and effective method of gene delivery to muscle resulting in long-term expression would be desirable.
Direct intramuscular plasmid DNA injection has proved to be a simple and safe way to deliver a gene construct in vivo. 11, [16] [17] [18] [19] [20] [21] Plasmid DNA delivered directly to muscle generally results in persistent albeit low-level gene expression since skeletal muscle takes up, episomally maintains and expresses plasmid DNA for a time notably longer than other tissues. 12, 25, [40] [41] [42] Furthermore, this method of gene delivery circumvents some of the problems encountered with viral vectors. Unlike viruses, the plasmid has no potential for reactivation to a pathogenic state and some authors have recently demonstrated that, following intramuscular injection, integration of plasmid DNA into muscle genomic DNA, should it occur, is an extremely rare event (the calculated rate of integration would be 3000 times lower than the accepted rate of spontaneous mutation rate for mammalian genome). 21, 43 In conclusion, our present study demonstrates the potential feasibility of the intramuscular gene transfer with naked plasmid DNA encoding apoE for the treatment of hyperlipidemic conditions. To date, however, several important issues remain to be addressed before this approach can be feasible for human gene therapy (ie higher levels of circulating proteins, increased efficiency of plasmid DNA uptake, increased half-life of the recombinant protein, systems for regulating recombinant gene expression, increased magnitude and temporal stability of transgene expression, 44 etc). Nevertheless, improvement of this method is anticipated to provide a new approach for the correction of a number of apolipoprotein deficiency states 45 and other hyperlipidemic conditions resulting in atherosclerosis. Our current studies provide data encouraging the use of direct i.m. naked gene transfer as an approach for long-term nonvirus or cell-based gene therapy.
Materials and methods
Plasmid vectors
Plasmid pCMV-E3, containing human apoE3 cDNA under the control of the CMV immediate-early promoterenhancer was constructed as previously described. 11 As negative controls, the pCMV5 and pRC112-HCV plasmid vectors were used. 22, 28 Plasmids were grown in Escherichia coli DH5 ␣ F1Ј and prepared as described elsewhere. 22 Animals and intramuscular injections C57BL/6J apoE-deficient mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and were maintained on a normal chow diet. 46 ApoE-deficient mice received injections of plasmid DNA dissolved in 225 mm NaCl. DNA injection was performed into the rectus femoris muscles using a disposable insulin syringe with a sterile 29-gauge needle. According to this protocol, apoE-deficient mice were injected with pCMV5 (sham control group) or pCMV-E3 (apoE group) plasmid DNA at 6-7 weeks of age. Blood was obtained by tail vein bleeding. Serum was isolated by centrifuging blood samples at 13 000 g for 10 min and stored at −80°C.
RT-PCR analysis
Total RNA was isolated by acid guanidinium thiocyanate-phenol chloroform extraction according to Chomczynski and Sacchi. 47 The first strand of cDNA was synthesized from 0.5-1 g of total RNA by incubation with 1 mm each dNTP, 20 U RNAsin, using the reverse primer (50 pmoles) and Promega (Charbonnières, France) AMV reverse transcriptase (15 U, 42°C, 1 h) in a final volume of 20 l. One quarter of a cDNA reaction was enzymatically amplified by PCR using human apoE3 specific primers (see below) and Taq DNA polymerase (2.5 U, Promega) in a reaction containing 1.5 mm MgCl 2 , 100 m each dNTP, and 25 pmoles of each primer, in a final volume of 50 l. The reactions were amplified using a programmable Perkin Elmer 480 thermocycler (Perkin Elmer/Applied Biosystems, Weiterstadt, Germany) for 40
Gene Therapy cycles of 1 min at 94°C, 1 min 30 s at 65°C, and 1 min 30 s at 72°C. To ensure specificity, each primer was selected from a region that distinguishes between human and mouse apoE3 cDNAs. Sequence of primers used was: forward DS3 5ЈTTGCTGGTCACATTCCTGG3Ј; reverse DS4 5ЈTCCGATTTGTAGGCCTTCAA3Ј. The expected size of the PCR product for human apoE3 was 263 bp. RT-PCR products were analyzed by PAGE.
Serum cholesterol assay
Total cholesterol serum concentrations were determined before and after treatment by microenzymatic procedures on samples collected by tail vein bleeding. Five microliters of serum was tested using the commercially available CHOD-PAP kit (Boehringer Mannheim, Mannheim, Germany), according to the manufacturer's instructions.
Lipoprotein analyses
Mouse serum was adjusted to a density of 1.21 g/ml with solid KBr and ultracentrifugation was performed for 4 h at 4°C using a Beckman TL-100 ultracentrifuge with a TLA 100.3 rotor (Beckman Instruments, Buckinghamshire, UK) at speed of 100 000 r.p.m. 48 After separation, top (d Ͻ 1.21 g/ml) and bottom (d Ͼ 1.21 g/ml) fractions were dialyzed against phosphate buffer saline (PBS) pH 7.4. The total protein concentration was determined by the method of Lowry et al. 49 Lipoprotein profile was determined by FPLC system (LKB) loading the d Ͻ 1.21 g/ml fraction on a Superose 6 gel permeation column (Pharmacia Biotech, Uppsala, Sweden). The column was eluted at a constant flow rate of 1 ml/min with 0.15 m NaCl, 0.01% (w/v) EDTA, 0.02% (w/v) NaN 3 , and 1 ml fractions were collected. Cholesterol content was determined by enzymatic procedures on a 150 l portion of each fraction.
Human apoE 'sandwich type' ELISA Human apoE in mouse serum was measured by using an antibody sandwich-type enzyme-linked immunoabsorbent assay (ELISA) with a mouse monoclonal (anti human apoE, Boehringer), as the capture antibody, and a goat polyclonal (Calbiochem, Novabiochem, La Jolla, CA, USA) as the detecting antibody. Values were determined by use of a standard curve obtained by the inclusion of different amounts of purified recombinant human apoE3 (Calbiochem) into serum of apoE-deficient mice or in PBS. Human serum samples at various dilutions were used as controls as well. Microtiter plates (Falcon, Becton Dickinson Labware, NJ, USA) were coated with the mouse monoclonal anti-human apoE antibody (5 ng/l) in Tris-buffered saline (TBS) pH 7.2 by incubation for 3 h at 37°C, followed by an overnight incubation at 4°C. The monoclonal solution was removed, and the plate was washed three times with TBS containing 0.05% Tween-20. The nonspecific protein binding sites in each well was blocked with TBS containing 1% bovine serum albumine (BSA) and allowed to incubate for at least 4 h at room temperature. The blocking buffer was removed and the plates were washed three times with TBS, 0.05% Tween-20. The standards and samples (50 l) were diluted in TBS and allowed to incubate overnight at 37°C. After five washes with TBS, 0.05% Tween-20, plates were incubated with 50 l per well of a 1:8000 dilution of the secondary anti-human apoE goat polyclonal antibody in TBS for 2 h at room temperature. The plates were washed five times and were then incubated with 50 l per well of a 1:5000 dilution of the tertiary rabbit anti-goat alkaline phosphatase-linked polyclonal antibody (Calbiochem). After standing for 1 h 30 min at room temperature, plates were washed five times with TBS, 0.05% Tween-20. Color reaction was developed by adding 50 l of substrate Pnitrophenyl/Phosphate Disodium (Sigma, St Louis, MO, USA) in diethanolamic buffer (1 ng/ml); after a 15-20 min RT incubation, reaction was stopped by the addition of 50 l of 1 N NaOH and absorbance was measured at 405 nm with a microplate reader (BioRad, Richmond, CA, USA). Standard curves were prepared from appropriate dilution, in apoE-deficient mice sera, of purified recombinant human apoE3 (Calbiochem) by plotting the absorbance at 405 nm as a function of the logarithm of apoE concentrations. Results were calculated from the best fitting least-squares parabola.
Statistical analysis
Statistical analyses were performed using the Sigma Stat program 1.02. Results are expressed as mean ± s.d. Intragroup data were analyzed by one way analysis of variance (ANOVA). Cholesterol concentrations in control and treated groups were compared using the two-tailed t test. Differences were considered statistically significant for P Ͻ 0.05.
